Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Brief Summary: This phase II trial studies how well cabozantinib s-malate, crizotinib, savolitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib s-malate, crizotinib, savolitinib, and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving cabozantinib s-malate, crizotinib, or savolitinib will work better in treating patients with kidney cancer compared to sunitinib malate.


Options:
A: Arm Label: Arm I (sunitinib malate); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Scan, Procedure: Computed Tomography, Drug: Sunitinib Malate | Arm Label: Arm II (cabozantinib s-malate); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Scan, Drug: Cabozantinib S-malate, Procedure: Computed Tomography | Arm Label: Arm III (crizotinib closed to accrual 12/5/18); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Scan, Procedure: Computed Tomography, Drug: Crizotinib | Arm Label: Arm IV (savolitinib closed to accrual 12/5/18); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Scan, Procedure: Computed Tomography, Drug: Savolitinib | Intervention Type: PROCEDURE; Name: Biospecimen Collection; Assigned to Arm(s): Arm I (sunitinib malate), Arm II (cabozantinib s-malate), Arm III (crizotinib closed to accrual 12/5/18), Arm IV (savolitinib closed to accrual 12/5/18) | Intervention Type: PROCEDURE; Name: Bone Scan; Assigned to Arm(s): Arm I (sunitinib malate), Arm II (cabozantinib s-malate), Arm III (crizotinib closed to accrual 12/5/18), Arm IV (savolitinib closed to accrual 12/5/18) | Intervention Type: DRUG; Name: Cabozantinib S-malate; Assigned to Arm(s): Arm II (cabozantinib s-malate) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (sunitinib malate), Arm II (cabozantinib s-malate), Arm III (crizotinib closed to accrual 12/5/18), Arm IV (savolitinib closed to accrual 12/5/18) | Intervention Type: DRUG; Name: Crizotinib; Assigned to Arm(s): Arm III (crizotinib closed to accrual 12/5/18) | Intervention Type: DRUG; Name: Savolitinib; Assigned to Arm(s): Arm IV (savolitinib closed to accrual 12/5/18) | Intervention Type: DRUG; Name: Sunitinib Malate; Assigned to Arm(s): Arm I (sunitinib malate)
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cediranib Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Cediranib Placebo; Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Temsirolimus | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon-Alfa 9MU | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Interferon-Alfa 9MU; Assigned to Arm(s): 2
D: Arm Label: Pembrolizumab+Axitinib Combination Therapy; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Axitinib | Arm Label: Sunitinib Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab+Axitinib Combination Therapy | Intervention Type: DRUG; Name: Axitinib; Assigned to Arm(s): Pembrolizumab+Axitinib Combination Therapy | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib Monotherapy

Answer: A